Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Argenteuil – page 16

3 430 clinical trials in Argenteuil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Argenteuil at a glance
3 430
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 430 trials in Argenteuil

Open in trial search

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trilaciclib dihydrochloride
  • Sponsor:Pharmacosmos A/S

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Asthma

Recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Embolism venous

Recruiting

Safety, Tolerability and Effect of RBD4059 Injection in Adults with Prior VTE After Anticoagulant Therapy and Cancer Patients at High Risk of VTE

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RBD4059
  • Sponsor:Ribocure Pharmaceuticals AB

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase II study of fixed‑dose, accelerated ramp‑up epcoritamab plus lenalidomide in patients with relapsed/refractory large B‑cell lymphoma after CAR‑T therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Argenteuil

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel treatment combinations and maintenance therapies. Studies include investigations of follicular lymphoma and chronic lymphocytic leukemia treatments.

  • Multiple Myeloma Therapy Optimization
  • Lymphoma Treatment Advances
  • Novel Drug Combinations

Particular emphasis on improving patient outcomes through targeted therapies and immunological approaches.

02 Immunology and Infectious Diseases

Clinical trials examining treatments for invasive candidiasis and immune system disorders. Research includes studies on immunosuppression prevention and management in intensive care settings.

  • Antifungal Treatments
  • Immune System Modulation
  • Critical Care Interventions

Focus on developing more effective treatments for both acute and chronic immune conditions.

03 Respiratory and Inflammatory Conditions

Studies investigating treatments for asthma and severe respiratory infections, including community-acquired pneumonia. Research includes evaluation of new delivery systems and therapeutic approaches.

  • Asthma Management
  • Pneumonia Treatment
  • Respiratory Drug Delivery

Emphasis on improving treatment outcomes and patient quality of life through innovative therapeutic strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.